GlassScriptPhysician profile
Clinton Rayhill
NPI 1700330008
$9,007.29
in general payments reported to CMS, 2019-2025
26 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,444 · 2022: $2,004 · 2023: $2,727 · 2024: $2,433 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,540 · Education: $19.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,539.63 |
| Education | $19.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.53 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,143.85 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $931.56 | 2021-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $751.94 | 2021-2025 | Rexulti |
| Alkermes, INC. | $610.75 | 2022-2024 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $456.11 | 2021-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Corium, LLC | $420.18 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $389.11 | 2021-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $375.89 | 2021-2024 | Hetlioz, Fanapt |
| Tris Pharma INC | $373.50 | 2022-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $338.31 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $334.67 | 2021-2024 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $314.39 | 2023-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $292.31 | 2022-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $284.33 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $134.38 | 2021-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $130.72 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Neos Therapeutics, LP | $103.05 | 2021-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $61.25 | 2023-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $45.62 | 2021-2022 | |
| Almatica Pharma LLC | $44.89 | 2022-2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $44.25 | 2025 | Jornay Pm |
| Tempus Ai, INC | $23.12 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.91 | 2022 | |
| Merck Sharp & Dohme LLC | $19.19 | 2022 | |
| Indivior INC. | $15.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Rayhill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.